<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00391248</url>
  </required_header>
  <id_info>
    <org_study_id>CTA-Control-105472</org_study_id>
    <nct_id>NCT00391248</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)</brief_title>
  <official_title>A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Patients With Non-small Cell Carcinoma of the Lung. (PEARL Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To improve the clinical outcomes of patients with non-small cell lung cancer treated with
      radiation therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean improvement of &quot;lung cancer symptoms&quot; as measured by the Lung Cancer Symptom Scale at four weeks following completion of radiation therapy</measure>
    <time_frame>4 weeks post radiotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The improvement in global quality of life and total scores of the LCSS at four weeks following treatment, radiological response, and the incidence and severity of adverse events as per the CTCAE version 3</measure>
    <time_frame>4 weeks post radiotherapy</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150 mg in a single daily dose, starting Day 1 through Day 22</description>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-small cell lung cancer (squamous cell, adenocarcinoma,
             poorly differentiated non-small cell carcinoma, or some combination of these); and

          -  Symptomatic patients (defined at discretion of investigator) for whom palliative
             thoracic radiation is planned (3000cGy/10 fractions); and

          -  At least 18 years of age.

        Exclusion Criteria:

          -  Previous erlotinib therapy; or

          -  Planned concurrent chemotherapy; or

          -  Expected survival of less than 3 months; or

          -  ECOG Performance Status of 3 or 4; or

          -  Multiple CNS metastasis or a single CNS lesion that has not demonstrated radiologic
             stability (screening CT/MRI or head not required); or

          -  Granulocyte count &lt;1,500/mm3, platelet count &lt;100,000/mm3, or haemoglobin &lt;9.0g/dl; or

          -  SGOT (AST) or SGPT (ALT) &gt; 2.5 times (x) upper limit of normal (ULN) in the absence of
             known liver metastases or &gt; 5 x ULN in case of known liver metastases; or

          -  Alkaline phosphatase (ALP) &gt; 2.5 x ULN; or

          -  Serum bilirubin &gt; 1.5 ULN; or

          -  Serum creatinine &gt; 1.5 ULN or creatinine clearance &lt; 60 ml/min; or

          -  Serum calcium beyond ULN; or

          -  Patients requiring systemic anti-fungal therapy, clarithromycin, phenytoin, or oral
             anticoagulation therapy (see Appendix VI for complete list of medications); or

          -  A history of interstitial lung disease; or

          -  Known sensitivity to erlotinib; or

          -  Pregnancy, lactation, or parturition within the previous 30 days; or

          -  Unwillingness or inability to complete the required assessments of the trial; or

          -  Mental incompetence, including psychiatric or addictive disorders which would preclude
             meaningful informed consent; or

          -  History of recurrent conjunctivitis or keratitis or other inflammatory changes of the
             surface of the eye.

          -  Geographically inaccessible for treatment or follow-up evaluations; or

          -  Involved in an ongoing therapeutic trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Wright, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sunnybrook Regional Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2006</study_first_submitted>
  <study_first_submitted_qc>October 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2006</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>palliative radiation</keyword>
  <keyword>tarceva</keyword>
  <keyword>palliative thoracic radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

